Introduction The success in the management of germ cell tumors has encouraged
researchers to pay more attention on long-term side effects and other survivorship issues …

The high cure rate of patients with advanced germ cell tumors is the result of effective
cisplatin-based chemotherapy; both previously untreated and relapsing patients can be …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …

In 2014, an estimated 8,820 new cases of testicular cancer will be diagnosed in the United
States [1]. Germ cell tumors remain a model for curative cancers, with more than 90% of all …

Opinion statement Patients with relapsed germ cell tumors (GCT) are potentially curable
despite the failure of initial cisplatin based therapy. The recent identification of robust …

Metastatic germ cell tumours (GCTs) are usually cured with cisplatin based chemotherapy
and standard treatment algorithms are established. However when this treatment fails and …

Although testicular germ cell tumors (GCTs) are a model for a curable neoplasm, a
significant proportion will relapse and require salvage therapy. While currently available …

Abstract Purpose of Review We review current management strategies for patients with
relapsed and refractory germ cell tumors (GCTs), defined as relapsed or persistent disease …

Introduction: Since the late nineties, the intensification of chemotherapy doses with
hematopoietic stem cell rescue held promise for patients with advanced and poor prognosis …

404 Background: Patients with germ cell tumors (GCT) that relapse after first-line platinum-
based chemotherapy can still be successfully rescued with second-line regimens. High …